Latest news
Merck (NYSE:MRK): Can new products offset the coming patent cliff? - Kalkine MediaKalkine Media · Fri, 07 Aug 2026 16:59:00 GMTBeyond the Crop Protection Patent Cliff: How Competitive Advantage Shifts After Patent Expiration - AgriBusiness GlobalAgriBusiness Global · Thu, 06 Aug 2026 16:27:53 GMTAs portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger - BioSpaceBioSpace · Tue, 04 Aug 2026 14:01:05 GMTThe Patent Cliff and the Drug Market’s Innovation Cycle - The American Action ForumThe American Action Forum · Tue, 04 Aug 2026 13:37:06 GMTEarnings Preview | Pfizer (PFE.US) and Merck (MRK.US) Announce Results on the Same Day: As Patent Cliff Meets New Growth Engines, the Pharmaceutical Industry Faces a Valuation Test - BitgetBitget · Tue, 04 Aug 2026 00:31:07 GMTGenerics/Biosimilars Outlook: Major Patent Cliff Looms Large - DCAT Value Chain InsightsDCAT Value Chain Insights · Thu, 30 Jul 2026 19:12:00 GMTSanofi's New Leadership Faces Looming Patent Cliff - MorningstarMorningstar · Thu, 30 Jul 2026 07:00:00 GMTNo-Moat Incyte Faces Jakafi Patent Cliff as Focus Remains on Opzelura and Expanding Portfolio - MorningstarMorningstar · Wed, 29 Jul 2026 23:50:19 GMT